Synonyms: compound 4a [PMID: 22019046] | CWP-403 | SK-0403 | SK0403 | Suiny®
anagliptin is an approved drug (Japan (2012))
Compound class:
Synthetic organic
Comment: Anagliptin (SkK-0403) is a dipeptidyl peptidase-4 (DPP4) inhibitor [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Anagliptin is approved in Japan and is used in the treatment of type 2 diabetes [2]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00532506 | Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus | Phase 2 Interventional | Sanwa Kagaku Kenkyusho Co., Ltd. | ||
NCT01169090 | A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy | Phase 2 Interventional | Kowa Research Institute, Inc. | ||
NCT01131091 | A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403 | Phase 1 Interventional | Kowa Research Institute, Inc. | ||
NCT01529541 | Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone | Phase 3 Interventional | JW Pharmaceutical | ||
NCT01529528 | A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients | Phase 3 Interventional | JW Pharmaceutical |